Who are BeBetter Med's main competitors?

Named competitors: Hengrui Medicine (600276.SS), BeiGene (688235.SS). The cockpit's measured peer set (industry) also includes Chengdu Easton Biopharmaceuticals (688513.SS), Zhejiang Tianyu Pharmaceutical (300702.SZ), Sichuan Huiyu Pharmaceutical (688553.SS), CStone Pharmaceuticals (2616.HK), Chongqing Taiji Industry (Group) (600129.SS), Viyash Scientific (VIYASH.NS).

How has BeBetter Med stock performed?

Over six months to 6 Nov 2026 the shares returned -48.8% against -15.2% for the median peer.

← CockpitCompetitor Analysis › 688759.SS BeBetter Med, Inc. Class AOpen in the cockpit ↗

BeBetter Med, Inc. Class A688759.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Guangzhou clinical-stage biotech developing small-molecule cancer drugs, largely pre-revenue.

≈ A small, China-based oncology biotechMomentum laggard 3

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$1.08B

US dollars, full cap

Free float

100%

of shares outstanding

$/day

$16.6M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

n/a

WACC 17.9%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥16.30

1D-2.9%

1W+7.6%

1M-21.4%

3M-24.6%

6M-48.8%

YTD-43.9%

1Yn/a

ATR %7.1%

52w lowhigh71.6% off high

What BeBetter Med does

Guangzhou clinical-stage biotech developing small-molecule cancer drugs, largely pre-revenue.

In one line: A small, China-based oncology biotech.

Products and services

Oncology drug candidates

Where it sits in the supply chain

Pharmaceuticals
Clinical-stage biotech
Oncology small molecules

What could go right

Positive trial data
Licensing deals with global pharma

What could go wrong

Trial failure risk
Ongoing cash burn

Moat: none (IP / patents). Value depends on unproven clinical pipeline rather than an approved product.

Headquarters: Guangzhou, China · Employees: 160

Named competitors

Hengrui Medicine 600276.SS
BeiGene 688235.SS

BeBetter Med at a glance

Size BeBetter Med (688759.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.08B, the 2150th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥16.30 on 6 Nov 2026.

Performance Over six months the shares fell 48.8%, against -15.2% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Relative performance

Six months, rebased to 100: BeBetter Med against the median of its 20 peers (local-currency closes).

BeBetter Med financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0
Revenue growth	—	—	—	—	—
Gross profit	CN¥0	-CN¥13.7M	-CN¥13.4M	-CN¥10.5M	-CN¥4.94M
EBITDA	n/a	-CN¥164M	-CN¥150M	-CN¥184M	-CN¥221M
Net income	-CN¥291M	-CN¥154M	-CN¥56.0M	-CN¥173M	-CN¥188M
Free cash flow	-CN¥261M	-CN¥109M	-CN¥107M	-CN¥145M	-CN¥170M
Capital expenditure	CN¥61.7M	CN¥10.7M	CN¥18.9M	CN¥18.3M	CN¥42.3M
Total debt	CN¥3.12M	CN¥4.39M	CN¥5.84M	CN¥6.08M	CN¥8.41M

Quarterly statements and history in the cockpit →

BeBetter Med competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. BeBetter Med is the large dot.

BeBetter Med competitors and peer comparison

Head to head with its named competitors (688759.SS vs 600276.SS vs 688235.SS)
Company	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g
BeBetter Med 688759.SS	$1.08B	-49%	n/a	n/a	n/a	n/a
Jiangsu Hengrui Pharmaceuticals 600276.SS	$49.7B	-6%	+6%	27%	8.8×	14.9%
BeOne Medicines 688235.SS	$45.8B	+19%	+28%	15%	6.8×	23.3%

How BeBetter Med compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BeBetter Med against its 20 peers (data as of 6 Nov 2026)
Measure	688759.SS	Peer median	Rank in peer set
1-month return	-21.4%	-5.5%	5th lowest of 21
6-month return	-48.8%	-15.2%	3rd lowest of 21
Distance from 52-week high	-71.6%	-35.5%	lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
BeBetter Med 688759.SS	China	$1.08B	-49%	n/a	n/a	n/a	n/a	n/a
Chengdu Easton Biopharmaceuticals 688513.SS	China	$1.09B	-35%	-2%	13%	4.5×	5.5%	+7.7%
Zhejiang Tianyu Pharmaceutical 300702.SZ	China	$1.08B	-2%	+27%	4%	2.4×	5.0%	+3.5%
Sichuan Huiyu Pharmaceutical 688553.SS	China	$1.07B	-15%	+8%	7%	4.7×	34.1%	-6.0%
CStone Pharmaceuticals 2616.HK	Hong Kong	$1.07B	-38%	+117%	-89%	14.8×	n/a	n/a
Chongqing Taiji Industry (Group) 600129.SS	China	$1.09B	-15%	-4%	2%	1.4×	n/a	n/a
Viyash Scientific VIYASH.NS	India	$1.07B	+3%	+96%	13%	3.2×	38.6%	+20.4%
Basilea Pharmaceutica BSLN.SW	Switzerland	$1.07B	+27%	+5%	24%	3.2×	-5.7%	+12.7%
Jiangxi Fushine Pharmaceutical 300497.SZ	China	$1.10B	-29%	+103%	24%	4.3×	8.6%	-4.5%
Ningbo Menovo Pharmaceutical 603538.SS	China	$1.10B	-51%	+19%	9%	4.3×	13.9%	+4.9%
Genfleet Therapeutics (Shanghai) 2595.HK	Hong Kong	$1.07B	-47%	-55%	-457%	68.9×	n/a	n/a
Bio-Thera Solutions 688177.SS	China	$1.10B	-14%	+24%	-44%	7.6×	n/a	n/a
China Resources Boya Bio-pharmaceutical 300294.SZ	China	$1.06B	-18%	-27%	-19%	3.0×	n/a	n/a
Renhe Pharmacy 000650.SZ	China	$1.06B	-10%	-7%	14%	1.0×	-9.4%	-7.0%
Blue Jet Healthcare BLUEJET.NS	India	$1.11B	+13%	-28%	28%	11.8×	49.0%	+13.8%
Shandong Lukang Pharmaceutical 600789.SS	China	$1.11B	-13%	-7%	3%	1.6×	3.3%	+6.5%
ST Pharm 237690.KS	South Korea	$1.12B	-52%	+26%	18%	3.8×	n/a	n/a
Jiangsu Kanion Pharmaceutical 600557.SS	China	$1.05B	-6%	+8%	7%	1.5×	3.4%	+1.8%
Sunflower Pharmaceutical 002737.SZ	China	$1.04B	-13%	+31%	-7%	1.8×	-6.4%	-7.7%
Zhejiang Jolly Pharmaceutical 300181.SZ	China	$1.13B	-18%	+17%	20%	2.5×	1.1%	+22.8%
Aurisco Pharmaceutical 605116.SS	China	$1.13B	-18%	+9%	28%	4.6×	1.5%	+18.7%

Questions

Who are BeBetter Med's main competitors?: Named competitors: Hengrui Medicine (600276.SS), BeiGene (688235.SS). The cockpit's measured peer set (industry) also includes Chengdu Easton Biopharmaceuticals (688513.SS), Zhejiang Tianyu Pharmaceutical (300702.SZ), Sichuan Huiyu Pharmaceutical (688553.SS), CStone Pharmaceuticals (2616.HK), Chongqing Taiji Industry (Group) (600129.SS), Viyash Scientific (VIYASH.NS).
How has BeBetter Med stock performed?: Over six months to 6 Nov 2026 the shares returned -48.8% against -15.2% for the median peer.